VRTX: Vertex Pharmaceuticals, Inc. Company Profile & Statistics

About

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Info & Links

CEO

Reshma Kewalramani

Headquarters

50 NORTHERN AVENUE
BOSTON, MA 02210, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

106

Employees

5,400

Vertex Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

102.28B

Enterprise Value

97.15B

Enterprise Value/EBITDA(ttm)

-1.92K

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

9.61

Price to Book(mrq)

6.55

Price to Cash(ytd)

27.06

Profitability

Gross Margin(ttm)

86.11%

Operating Margin(ttm)

-2.99%

Profit Margin(ttm)

-4.69%

Return on Equity(ttm)

-1.91%

Return on Invested Capital(ttm)

-5.91%

Return on Assets(ttm)

-1.43%

Income Statement

Revenue(ttm)

10.63B

Revenue Per Share(ttm)

41.26

Gross Profit(ttm)

9.15B

EBITDA(ttm)³

-50.70M

Net Income Available to Common(ttm)

-479.80M

Diluted EPS(ttm)

-1.99

Share Statistics

Beta (5Y Monthly)

0.36

52-Week Change

13.27%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

257.53M

Dividend Yield

0.00%

Float⁴

257.01M

% Held by Insiders

0.20%

% Held by Institutions

90.96%

Balance Sheet

Total Cash(mrq)

6.52B

Total Cash Per Share(mrq)

25.33

Total Debt(mrq)

114.00M

Total Debt/Equity(mrq)

0.73%

Current Ratio(mrq)

2.47%

Quick Ratio(mrq)

2.20%

Book Value Per Share(mrq)

60.65

Cash Flow

Operating Cash Flow Per Share(ytd)

-4.13

Free Cash Flow(ytd)

-1.28B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

VRTX

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals, Inc. Profile